{
    "organizations": [],
    "uuid": "228581be5321817fb741611b2bceb534f125c7eb",
    "author": "",
    "url": "https://www.reuters.com/article/brief-pfizer-doses-first-patient-using-i/brief-pfizer-doses-first-patient-using-investigational-mini-dystrophin-gene-therapy-for-the-treatment-of-duchenne-muscular-dystrophy-idUSFWN1RP0KL",
    "ord_in_thread": 0,
    "title": "BRIEF-Pfizer Doses First Patient Using Investigational Mini Dystrophin Gene Therapy For The Treatment Of Duchenne Muscular Dystrophy",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 12, 2018 / 12:04 PM / Updated 8 minutes ago BRIEF-Pfizer Doses First Patient Using Investigational Mini Dystrophin Gene Therapy For The Treatment Of Duchenne Muscular Dystrophy Reuters Staff \nApril 12 (Reuters) - Pfizer Inc: \n* DYSTROPHIN GENE THERAPY FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY \n* DYSTROPHIN GENE THERAPY STUDY TRIAL ARE EXPECTED IN FIRST HALF OF 2019 Source text for Eikon: Further company coverage:",
    "published": "2018-04-12T15:02:00.000+03:00",
    "crawled": "2018-04-12T15:18:03.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "pm",
        "updated",
        "minute",
        "ago",
        "dos",
        "first",
        "patient",
        "using",
        "investigational",
        "mini",
        "dystrophin",
        "gene",
        "therapy",
        "treatment",
        "duchenne",
        "muscular",
        "dystrophy",
        "reuters",
        "staff",
        "april",
        "reuters",
        "pfizer",
        "inc",
        "dystrophin",
        "gene",
        "therapy",
        "treatment",
        "duchenne",
        "muscular",
        "dystrophy",
        "dystrophin",
        "gene",
        "therapy",
        "study",
        "trial",
        "expected",
        "first",
        "half",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}